logo
TuSimple Reportedly Shared Self-Driving Data With China

TuSimple Reportedly Shared Self-Driving Data With China

Yahoo29-05-2025

TuSimple—now known as CreateAI—shared sensitive data with a Beijing-owned company after it signed an agreement with the U.S. government promising to stop sharing such data with firms in China, the Wall Street Journal reported Tuesday.
In February 2022, TuSimple signed the agreement, targeted at protecting national security. It had six months to begin complying with the order, which stipulated the company would disentangle its business and its burgeoning technology from The Committee on Foreign Investment (CFIUS) was responsible for ensuring TuSimple's compliance with the agreement.
More from Sourcing Journal
US-Based Chinese Logistics Firms Caught Using Counterfeit USPS Labels
FedEx Freight Taps New CEO, Chairman Ahead of 2026 Spinoff
Yellow Nets $14M in Terminal Sales, Sets Up Saia to Further Expand US Footprint
WSJ reported TuSimple sent data to Chinese autonomous vehicles a week after the agreement was signed by both entities.
According to WSJ, the interagency body found that TuSimple's data sharing didn't violate that agreement; nonetheless, it did find other contraventions, which saw TuSimple paying a $6 million settlement fee, albeit without accepting fault for the issues CFIUS reportedly found.
The Journal further noted that TuSimple in 2021—prior to the CFIUS agreement—brokered a deal between Chinese companies Foton and Hydron that would see the two developing autonomous trucks together, while Hydron shared an office with TuSimple.
The publication further noted that TuSimple subsequently shared documents detailing how to build the autonomous vehicles it had built in the U.S.—including information about brakes, chips, steering, servers and powering the vehicle and noted that the sharing continued after the CFIUS agreement had been signed, until the compliance period officially began. WSJ reported that one of TuSimple's founders denied having sent any such information to Hydron and denied any involvement with Foton, despite the Journal having seen evidence to the contrary.
TuSimple's tango with CFIUS was far from its only regulatory ruckus during this time; the U.S. Securities and Exchange Commission (SEC) also investigated TuSimple in 2022, with a special interest in the relationship between the company and Hydron. Public documentation shows that TuSimple indicated it had come to a settlement agreement with the SEC that just needed to be finalized, but the CFIUS investigation—and another investigation brought against TuSimple by the Commerce Department because of its purported relationship with technology giant Nvidia.
But TuSimple, in the form that it was then, is long gone. In January 2024, the company announced that it would delist from the Nasdaq, citing cost-value imbalances. That move came after layoffs and issues with venture capital funding, which later saw TuSimple auctioning off 10 of its autonomous big rigs.
In its place is CreateAI, which leverages generative AI to create video content. That venture, stood up in December 2024, comes after TuSimple vacated the U.S. market; the company told TechCrunch that despite its efforts to operate an autonomous vehicle business in China, its agreement with CFIUS made such an attempt extremely difficult. CreateAI is funded by some of the money left in TuSimple's wake
But CreateAI isn't the only venture that TuSimple alumni are involved with; according to WSJ, Xiaodi Hou, one of the company's founders, has started a new company based out of Texas called Bot Auto. He has recruited ex-TuSimple employees.
Sourcing Journal could not reach CreateAI, formerly TuSimple, for comment.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What Texas Instruments Capital Strength Means for Its Dividend
What Texas Instruments Capital Strength Means for Its Dividend

Yahoo

time12 minutes ago

  • Yahoo

What Texas Instruments Capital Strength Means for Its Dividend

Texas Instruments Incorporated (NASDAQ:TXN) is one of the Best Stocks to Buy for Dividends. A robotic arm in the process of assembling a complex circuit board - showing the industrial scale the company operates at. The company follows a strong business model centered on analog and embedded processing products, supported by its long-lasting competitive strengths. Another key part of its strategy to drive long-term growth in free cash flow per share is its disciplined approach to capital allocation. This includes careful selection of research and development projects, building new capabilities, investing in manufacturing capacity, evaluating potential acquisitions, and returning capital to shareholders. Texas Instruments Incorporated (NASDAQ:TXN)'s strategy also focuses on efficiency, which it defines as consistently aiming to generate greater results for every dollar spent. This approach emphasizes directing investments toward the most impactful areas to support the long-term growth of free cash flow per share, rather than simply cutting costs to the bare minimum. For shareholders, this commitment to efficiency is expected to support revenue growth, stronger gross margins, careful management of R&D and SG&A expenses, healthy free cash flow margins, and ultimately, an increase in free cash flow per share. Texas Instruments Incorporated (NASDAQ:TXN) currently offers a quarterly dividend of $1.36 per share. Overall, the company has raised its payouts for 21 consecutive years. In the past five years, it has raised its payouts at an annual average rate of over 9%, which is considered a solid pace in the tech sector. As of June 25, TXN has a dividend yield of 2.65%. While we acknowledge the potential of TXN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Yahoo

time32 minutes ago

  • Yahoo

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ardelyx (ARDX) Appoints New Chief Business and HR Officers
Ardelyx (ARDX) Appoints New Chief Business and HR Officers

Yahoo

time32 minutes ago

  • Yahoo

Ardelyx (ARDX) Appoints New Chief Business and HR Officers

Ardelyx, Inc. (NASDAQ:ARDX) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company announced two key appointments to its leadership team. Mike Kelliher, who joined the company in March 2024, was promoted from his previous role as Executive Vice President, Corporate Development and Strategy to Chief Business Officer (CBO). James P. Brady joined Ardelyx as the new Chief Human Resources Officer (CHRO). Both Kelliher and Brady report directly to Mike Raab, the company's President and CEO. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. Ardelyx said that these appointments are part of its strategy to strengthen its leadership team. The move, the company stated, is crucial to advancing its commercial and clinical programs. 'As we continue to grow and evolve our business, it is imperative that we have high caliber leaders, like Mike and Jamie, who will enable us to accelerate our momentum and deliver long-term impact for patients and shareholders,' said Raab. The CEO highlighted Kelliher's experiences, business intuition, and leadership as bringing 'incredible value' to Ardelyx. On the other hand, he expressed excitement about welcoming Brady, emphasizing his talent as an HR executive and his extensive experience in people development, which will be influential in advancing key business initiatives and talent strategies. Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company. It discovers, develops, and commercializes first-in-class medicines for gastrointestinal and kidney diseases. Its key products include IBSRELA (for irritable bowel syndrome with constipation) and XPHOZAH (a phosphate absorption inhibitor for chronic kidney disease patients on dialysis). Ardelyx serves adult patients in the United States and internationally. While we acknowledge the potential of ARDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store